Association of catechol-O-methyltransferase Val158Met polymorphism with fibromyalgia risk and FIQ scores: an updated meta-analysis

Author information

CER18193
2025 Vol.43, N°6
PI 1002, PF 1009
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 40153322 [PubMed]

Received: 28/09/2024
Accepted : 25/11/2024
In Press: 24/03/2025
Published: 26/06/2025

Abstract

OBJECTIVES:
To investigate associations of catechol-O-methyltransferase (COMT) Val158Met polymorphism with susceptibility to fibromyalgia and Fibromyalgia Impact Questionnaire (FIQ) score in patients with fibromyalgia (FM).
METHODS:
A comprehensive search was carried out across the Medline, Embase, and Web of Science databases to identify pertinent articles. A meta-analysis was then conducted to evaluate the relationship between the COMT Val158Met polymorphism and both the risk of developing FM and the Fibromyalgia Impact Questionnaire (FIQ) score.
RESULTS:
The meta-analysis included 2,115 patients and 1,867 controls from 16 studies on COMT Val158Met polymorphism and 1,199 patients from eight studies on COMT Val158Met polymorphism and FIQ score in FM. Findings revealed an association between FM and COMT Met allele across all study subjects (OR: 1.375, 95% CI: 1.076–1.757, p=0.001). However, regional stratification showed no association between the COMT Met allele and FM in European, Latin American, or Asian populations. The same pattern was observed using recessive, dominant, and homozygote contrast models for the COMT Met allele. Furthermore, the FIQ score was significantly higher in patients with the COMT Met/Met genotype than in those with the Val/Val genotype (WMD: 11.24, 95% CI: 4.742-17.74, p=0.001) and the Val/Met genotype (WMD: 5.950, 95% CI: 2.017-9.893, p=0.003).
CONCLUSIONS:
This meta-analysis indicates significant associations of COMT Val158Met polymorphism with both FM risk and FIQ score in FM patients.

DOI: https://doi.org/10.55563/clinexprheumatol/8njnoh